Pharma

Pharma·

Onco-Innovations Limited: Successful Scaling of the Pharmaceutical Active Ingredient A83B4C63 and Appointment of a New CFO

CA68237C1059CA68237C1059
CA68237C1059
Pharma·

US Government Investigates Drug Prices in Germany: A Warning Signal for the Pharmaceutical Industry

US5324571083US5324571083US7170811035US7170811035
US5324571083
Pharma·

Novo Nordisk: Challenges and Opportunities in Focus for Investors

DK0060534915DK0060534915
DK0060534915
Pharma·

Onco-Innovations Successfully Completes Project with Kuano and Optimizes PNKP Inhibitor Technology

CA68237C1059CA68237C1059
CA68237C1059
Pharma·

BioNxt Solutions Inc. Focuses on Strategic Partnerships for Marketing BNT23001

CA0909741062CA0909741062
CA0909741062
Pharma·

Vidac Pharma Holding PLC: Recruitment in Phase 2B Study with VDA-1102 Successfully Completed

GB00BM9XQ619GB00BM9XQ619
GB00BM9XQ619
Pharma·

Onco-Innovations Starts Process Development for Innovative PNKP Inhibitor Technology

CA68237C1059CA68237C1059
CA68237C1059
Pharma·

Eli Lilly's Next-Gen Weight-Loss Drug Sparks Shareholder Optimism

US5324571083US5324571083
US5324571083
Pharma·

Zealand Pharma Faces Setback as Weight-Loss Drug Trial Sees High Discontinuation Rates

DK0060946788DK0060946788
DK0060946788
Pharma·

Pharmaceutical Industry Under Pressure: Challenges from New Discount Regulations

DE0005068404DE0005068404
DE0005068404
Pharma·

Wegovy Continues to Lead the GLP-1 Market Despite New Entrants

US5324571083US5324571083DK0060534915DK0060534915
US5324571083
Pharma·

Pharmaceutical Industry in Germany Under Pressure: Investment Cancellations as a Warning Signal

US5324571083US5324571083
US5324571083
Pharma·

Emerging Weight-Loss Therapies Poised to Outshine GLP-1s

Pharma·

Pharmaceutical Industry in Germany: Warning Signals from Canceled Investments

US5324571083US5324571083
US5324571083
Pharma·

Merck to Settle Gardasil Lawsuits for $50 Million: A Strategic Move Amid Controversy

US58933Y1055US58933Y1055
US58933Y1055
Pharma·

Roche Chairman Accuses US Government of Drug Price ‘Blackmail’

CH0012032048CH0012032048
CH0012032048
Pharma·

Gedeon Richter Presents Growing Biosimilar Portfolio at EULAR 2026

HU0000123096HU0000123096
HU0000123096
Pharma·

Parabilis Medicines Aims for $475 Million IPO to Accelerate Cancer Drug Development

Pharma·

Earli's Roeding Highlights China's Biotech Ascendancy

Pharma·

Lilly and BioNTech Sound Alarm on German Health Reforms Impacting Investment

US5324571083US5324571083US09075V1026US09075V1026
US5324571083
Pharma·

Eli Lilly Expands Genetic Medicine Footprint with $1.9 Billion Ascidian Pact

US5324571083US5324571083
US5324571083
Pharma·

Boehringer Ingelheim Stops Billion-Euro Investments in Germany

Pharma·

Boehringer Ingelheim Stops Investments in Germany: A Signal for the Pharmaceutical Industry

Pharma·

Onco-Innovations: Advances in Scaling B4 Precursor Production and New Marketing Program

CA68237C1059CA68237C1059
CA68237C1059
Pharma·

MindWalk Holdings Corp. Presents Promising Preclinical Data for Dengue Vaccine Development

US1234567890US1234567890
US1234567890
Pharma·

Abivax's Ulcerative Colitis Breakthrough: A Catalyst for Growth and Acquisition

FR0014005R82FR0014005R82
FR0014005R82
Pharma·

Barclays Recommends Astrazeneca: Positive Outlook for the Datroway Program

GB0009895292GB0009895292
GB0009895292
Pharma·

‘King Keytruda’ Faces New Challenger as Ivonescimab Shows Promise

US58933Y1055US58933Y1055
US58933Y1055
Pharma·

Apotex Health Aims for C$1.2 Billion IPO: A Growth Opportunity in the Generic Drug Market

Pharma·

Akeso Targets Expansion in Lung Cancer Drug Manufacturing Amid Rising Demand

KYG0146B1032KYG0146B1032
KYG0146B1032